Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2020-05-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
关于修改《公司章程》的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of 马应龙药业集团股份有限公司 regarding the proposed amendments to the company's Articles of Association (公司章程). It details changes to the company's business scope and states that the amendments will be submitted to the shareholders' meeting for approval. The document is short (1140 characters) and does not contain financial data, audit information, or detailed reports. It is not a full report but an announcement of a governance-related change. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes in company governance documents or management decisions.
2020-05-25 Chinese
第十届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 7th meeting of the 10th Board of Directors of Mayinglong Pharmaceutical Group Co., Ltd. It details board decisions on increasing the limit for entrusted financial management of idle funds, amending the company's articles of association, and scheduling the 2019 Annual General Meeting. The document includes voting results and references to further announcements published elsewhere. It does not contain financial statements or detailed financial data, nor is it a report itself. It is an announcement of board meeting resolutions, specifically about board decisions and governance matters. Therefore, it fits best under 'Board/Management Information' (MANG). The document length is short (1241 characters), and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2020-05-25 Chinese
2019年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2019 by 马应龙药业集团股份有限公司. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2019, including financial and non-financial internal control defects, standards for defect classification, and the scope of the evaluation. The content is focused on internal control assessment rather than a full annual report or audit report. It is a standalone report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it relates to internal control results and applied standards, but is not a full annual report (10-K) or interim report. The document length is 4642 characters, which is sufficient to contain substantive content rather than a mere announcement. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2019
2020-04-24 Chinese
关于马应龙药业集团股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2020-04-24 Chinese
2019年度审计报告
Regulatory Filings
2020-04-24 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company 马应龙药业集团股份有限公司 regarding changes in accounting policies. It references specific accounting standards updates issued by the Ministry of Finance and explains the nature and impact of these changes. The document includes statements from the board of directors, independent directors, and the supervisory board approving the changes. It does not contain actual financial statements or detailed financial data but rather explains the policy changes and their expected effects. The document length is 2610 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The content fits best with a Regulatory Filing (RNS) as it is a formal disclosure of accounting policy changes required by regulatory authorities but does not constitute a full financial report itself.
2020-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.